Brooklyn ImmunoTherapeutics, Inc. - Common Stock (BTX)

Competitors to Brooklyn ImmunoTherapeutics, Inc. - Common Stock (BTX)

Advaxis, Inc.

Advaxis is also focused on developing immunotherapies for cancer and infectious diseases, positioning itself similarly to Brooklyn ImmunoTherapeutics. Despite this, Advaxis has a longer history in clinical trials and a more established product pipeline, which provides it a competitive edge in gaining approval and market share for its treatments.

Agenus Inc. 

Agenus is involved in the development of immuno-oncology therapies, including antibodies and cell therapies, which overlap with the focus areas of Brooklyn ImmunoTherapeutics. Agenus has a diverse and advancing pipeline, along with collaborations with larger pharmaceutical companies that lend credibility and resources to their clinical programs, placing it ahead of Brooklyn in terms of therapeutic breadth and strategic partnerships.

CureVac N.V. 

CureVac focuses on mRNA technology for therapeutic and vaccine development, targeting similar diseases as Brooklyn ImmunoTherapeutics. Both companies are working on advanced therapeutic modalities and share a vision for innovative treatment approaches. However, CureVac's extensive collaborations, strong financial backing, and established relationships in the biopharmaceutical sector give it a competitive edge in the development and commercialization of its therapies.

Novavax, Inc. 

Novavax specializes in the development of vaccines and immunotherapy solutions, and it has been a key player in the response to infectious diseases, including COVID-19. While Brooklyn ImmunoTherapeutics targets specific therapeutic areas, Novavax's broader portfolio of infectious disease vaccines gives it an advantage in terms of market presence and recognition among investors and healthcare providers.

OncoSec Medical Incorporated

OncoSec is engaged in the development of intratumoral immunotherapies, similar to some of Brooklyn ImmunoTherapeutics’ focus areas. Both companies are aiming at enhancing cancer treatment through innovative delivery mechanisms. However, OncoSec’s proprietary technology and partnerships with key research institutions give it an advantage in clinical trials and market outreach.